| Patient | Judy Garland |
|---|---|
| Date of birth | 1922-06-10 |
| Identifiers | MRN HR-ML005-SYN-TD; SSN (made up) 000-05-6127 |
| Document date | 1955-10-26 |
| Author | Margaret Ellsworth-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-month review: phenobarbital taper, sleep, mood and laboratory checks. [S]
Ms. Garland returns four weeks after her preventive visit. She lowered phenobarbital to 40.5 mg a day at that visit and to 32.4 mg a day two weeks ago. After the last step she lay awake for three nights and felt shaky inside, without a tremor others could see; it has eased but not fully gone, and she would like to stay at this dose for a while. She has taken no secobarbital, stimulant or other sedative. She sleeps about six hours on most nights. Her mood is good and she is enjoying work again. She eats three meals on most days and says she feels stronger. Her HIV, hepatitis C and hepatitis B tests from the preventive visit were nonreactive, and she was told by phone. She wants to talk about stopping smoking once the taper is over. [S]
| Element | Detail |
|---|---|
| Phenobarbital | 32.4 mg a day for two weeks; three nights of rebound wakefulness after the step |
| Other sedatives or stimulants | None |
| Sleep | About six hours; Insomnia Severity Index 10 |
| Mood | PHQ-9 5; GAD-7 5 |
| Screening results | HIV, hepatitis C and hepatitis B nonreactive |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight up gradually |
| Neurological | Negative | No visible tremor or seizure-like episodes; brief inner shakiness after the last step, easing |
| Psychiatric | Negative | Mood good; PHQ-9 5; no thoughts of suicide or self-harm |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine | Two capsules at bedtime; no extra doses | Oral route | 1955-06-22 to 1955-07-06 | completed | S |
| Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy | One tablet each morning | Oral route | 1955-06-22 to 1955-07-20 | completed | S |
| Dextroamphetamine 5 mg oral tablet, one tablet each morning for two weeks, then stop | One tablet each morning for two weeks, then stop | Oral route | 1955-07-20 to 1955-08-03 | completed | S |
| Sertraline 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1955-06-22 to 1955-06-29 | completed | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1955-06-29 | active | S |
| Phenobarbital 32.4 mg oral tablet, one tablet three times daily (97.2 mg a day), started in hospital in place of secobarbital | One tablet three times daily | Oral route | 1955-07-06 to 1955-07-20 | completed | S |
| Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a time | Per the written taper schedule, in two or three divided doses | Oral route | 1955-07-20 | active | S |
| Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks | 150 mg intramuscularly every 13 weeks | Intramuscular route | 1955-06-22 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for throat pain, no more than 3,000 mg a day, for up to five days | Two tablets every 6 hours as needed, up to 3,000 mg a day | Oral route | 1955-08-17 to 1955-08-22 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1955-10-26 | Body height | 151 | cm | S |
| 1955-10-26 | Body weight | 50 | kg | S |
| 1955-10-26 | Body mass index (BMI) [Ratio] | 21.9 | kg/m2 | S |
| 1955-10-26 | Systolic blood pressure | 112 | mm[Hg] | S |
| 1955-10-26 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1955-10-26 | Heart rate | 68 | /min | S |
| 1955-10-26 | Respiratory rate | 14 | /min | S |
| 1955-10-26 | Body temperature | 36.6 | Cel | S |
| 1955-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1955-10-26 | Hemoglobin [Mass/volume] in Blood | 12.9 | g/dL | 12-15.5 g/dL | Normal | S |
| 1955-10-26 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 87 | fL | 80-100 fL | Normal | S |
| 1955-10-26 | Platelets [#/volume] in Blood by Automated count | 268 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1955-10-26 | Ferritin [Mass/volume] in Serum or Plasma | 41 | ng/mL | 15-150 ng/mL | Normal | S |
| 1955-10-26 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1955-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1955-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.68 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1955-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M | 118 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1955-10-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 10-35 U/L | Normal | S |
| 1955-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 7-35 U/L | Normal | S |
| 1955-10-26 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 48 | U/L | 5-40 U/L | High | S |
| 1955-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1955-10-26 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S |
Vital signs recorded on 1955-10-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 112/70, pulse 68; weight 50.0 kg, BMI 21.9 |
| Neurological | No tremor with arms outstretched; no nystagmus |
| Psychiatric | Bright and engaged; no signs of sedation or withdrawal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pills | active | confirmed | F13.20 | S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis. |
| Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pills | active | confirmed | F15.10 | S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription. |
| Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescence | active | confirmed | G47.00 | S — Synthetic modern diagnosis anchored to the documented sleeping pills. |
| Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implants | active | confirmed | Z30.013 | S — Synthetic contraception need; the birth is documented. |
| Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used. |
| Acute laryngitis, probably viral, during rehearsals, treated with voice rest and supportive care; resolved | resolved | confirmed | J04.0 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Barbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs) | Every visit | Completed today | 32.4 mg a day; mild rebound wakefulness after the last step; no tremor or other withdrawal signs |
| Medication safety | Taper pace | Reductions of no more than about 20% every two weeks, slower toward the end; pause for symptoms, illness or a major performance | Completed today | 56.7 to 48.6 to 40.5 to 32.4 mg a day at two-week intervals; paused today for four weeks; later steps of 8.1 mg |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's prescriptions |
| Laboratory | Urine drug testing, explained as part of care | At the start, after the change to phenobarbital, and periodically during the taper | Completed today | Barbiturates only; amphetamine negative |
| Medication safety | Limited dispensing, locked storage and take-back of unused capsules | Seven days at first, then two weeks at a time | Completed today | Two-week supplies; locked box |
| Medication safety | Mood, sleep, energy and appetite after stopping the stimulant | Each visit | Completed today | No stimulant for twelve weeks; urges rare |
| Laboratory | Blood count and liver tests on phenobarbital | Baseline, then at three to four months | Completed today | Hemoglobin 12.9 g/dL, MCV 87 fL, platelets 268; ferritin 41 ng/mL; sodium 140, potassium 4.2, creatinine 0.68 mg/dL, eGFR 118; AST 23, ALT 20 U/L; GGT 48 U/L, mildly raised by enzyme induction |
| Survey | CBT for insomnia, sleep diary and Insomnia Severity Index | Weekly CBT-I sessions; sleep diary and index at each visit | Completed today | Insomnia Severity Index 10 |
| Medication safety | New hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine) | Not recommended as a replacement | Not indicated | No new hypnotic |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Completed today | PHQ-9 5, item 9 scored 0; monthly since the corrective action |
| Survey | Anxiety (GAD-7) | With each PHQ-9 while anxiety is treated | Completed today | GAD-7 5 |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | 50 mg daily; no side effects |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; the 988 Suicide & Crisis Lifeline in her phone |
| Examination | Weight, meals and disordered-eating screen, without a weight target | Every visit | Completed today | Weight 50.0 kg, BMI 21.9; three meals on most days; she feels stronger |
| Medication safety | Contraception that phenobarbital does not weaken | Medroxyprogesterone every 13 weeks | Up to date | Second injection at the preventive visit; next due in nine weeks |
| Medication safety | Naloxone | Reassess at every visit and whenever an opioid is prescribed | Not indicated | No opioids prescribed or used |
| Self-management | Alcohol and other sedatives | Every visit | Completed today | No alcohol; no other sedatives |
Goal progress:
Guideline basis: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024); Prescription Drug Monitoring Programs (PDMPs) (2026); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Nurse phone check before each remaining step. Visit in four weeks to restart the taper. Addiction medicine review when the taper ends. Smoking cessation plan at the end of the taper. [S]